| 1. |
|
|
| 2. |
- Yusuf, D, et al.
(författare)
-
The transcription factor encyclopedia
- 2012
-
Ingår i: Genome biology. - : Springer Science and Business Media LLC. - 1474-760X .- 1465-6906. ; 13:3, s. R24-
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Reinap, A., et al.
(författare)
-
Direct Conductor Cooling in Concentrated Windings
- 2018
-
Ingår i: Proceedings - 2018 23rd International Conference on Electrical Machines, ICEM 2018. - 9781538624777 ; , s. 2654-2660
-
Konferensbidrag (refereegranskat)abstract
- This paper presents and assesses the cooling integration of electrical machines with concentrated windings. A conventional coil in a concentrated winding with forced cooling applied on the exterior coil surfaces is replaced by an alternative solution where the coil is opened up in a laminar structure with the intention of the coolant fluid penetrating the coil and removing the interior heat. This is a purely theoretical study where a set of FE models are used to evaluate the torque capability under elevated thermal loads, comparing conventional to alternative cooling integration topologies. The objective of the unsophisticated FE evaluation models and simple design rules is to demonstrate the potential of the laminated type of windings where the space between the current carrying flat conductors is used to circulate coolant so that the heat losses are removed in the vicinity of where they are generated. Conjugate heat transfer analysis in Comsol multiphysics based on 2D and 3D is used to demonstrate the cooling capability for air and oil cooled windings up to thermal loads corresponding to 50 A/mm2at 24 nΩm and a target hot spot temperature of 120°C for copper.
|
|
| 6. |
- Wang, Michael L., et al.
(författare)
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
- 2022
-
Ingår i: New England Journal of Medicine. - 0028-4793. ; 386:26, s. 2482-2494
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma. METHODS We randomly assigned patients 65 years of age or older to receive ibrutinib (560 mg, administered orally once daily until disease progression or unacceptable toxic effects) or placebo, plus six cycles of bendamustine (90 mg per square meter of body-surface area) and rituximab (375 mg per square meter). Patients with an objective response (complete or partial response) received rituximab maintenance therapy, administered every 8 weeks for up to 12 additional doses. The primary end point was progression-free survival as assessed by the investigators. Overall survival and safety were also assessed. RESULTS Among 523 patients, 261 were randomly assigned to receive ibrutinib and 262 to receive placebo. At a median follow-up of 84.7 months, the median progression-free survival was 80.6 months in the ibrutinib group and 52.9 months in the placebo group (hazard ratio for disease progression or death, 0.75; 95% confidence interval, 0.59 to 0.96; P=0.01). The percentage of patients with a complete response was 65.5% in the ibrutinib group and 57.6% in the placebo group (P=0.06). Overall survival was similar in the two groups. The incidence of grade 3 or 4 adverse events during treatment was 81.5% in the ibrutinib group and 77.3% in the placebo group. CONCLUSIONS Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs.
|
|
